SEC Tracker
Get the app

Vyome Holdings HIND

Vyome Holdings Q3 FY25: revenue $35K, down 59%; diluted EPS −$3.12

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Vyome Holdings reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$35K−59% from $85K in Q3 FY2410-Q income statement, on EDGAR
  2. Net income−$8.4MAgainst −$1.6M in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$3.12Against −$4,520.35 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.7M+668% from $743K in Q3 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$4.3MAgainst −$311K in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Vyome Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025
  4. Natural Alternatives International NAII public float $6M, Dec 31, 2025
  5. LFTD Partners LIFD public float $6M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.